{"name":"TenNor Therapeutics (Suzhou) Limited","slug":"tennor-therapeutics-suzhou-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Bismuth potassium citrate placebo capsules","genericName":"Bismuth potassium citrate placebo capsules","slug":"bismuth-potassium-citrate-placebo-capsules","indication":"Control arm in Phase 3 clinical trial (specific indication unknown)","status":"phase_3"},{"name":"Clarithromycin placebo tablets","genericName":"Clarithromycin placebo tablets","slug":"clarithromycin-placebo-tablets","indication":"Control arm in phase 3 clinical trial (active indication unknown)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Rifasutenizol capsules","genericName":"Rifasutenizol capsules","slug":"rifasutenizol-capsules","indication":"Tuberculosis (pulmonary and extrapulmonary)","status":"phase_3"}]}],"pipeline":[{"name":"Bismuth potassium citrate placebo capsules","genericName":"Bismuth potassium citrate placebo capsules","slug":"bismuth-potassium-citrate-placebo-capsules","phase":"phase_3","mechanism":"This is a placebo formulation containing bismuth potassium citrate with no active therapeutic mechanism.","indications":["Control arm in Phase 3 clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Clarithromycin placebo tablets","genericName":"Clarithromycin placebo tablets","slug":"clarithromycin-placebo-tablets","phase":"phase_3","mechanism":"This is a placebo tablet with no active pharmacological mechanism.","indications":["Control arm in phase 3 clinical trial (active indication unknown)"],"catalyst":""},{"name":"Rifasutenizol capsules","genericName":"Rifasutenizol capsules","slug":"rifasutenizol-capsules","phase":"phase_3","mechanism":"Rifasutenizol is a rifamycin-class antibiotic that inhibits bacterial RNA polymerase to prevent transcription and translation in mycobacteria.","indications":["Tuberculosis (pulmonary and extrapulmonary)","Drug-resistant tuberculosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNTW5PRHRPckU4NnlPRkZNVTNkZ3pXa2pkeFVTUFk1VG1WY19ZVFNtd2dVblJHM2UtZWpQZUswT2NwMjhQRUNpejRsQzBLZ2VveGQ4UTYzSnJ2bG9NYmpkNHRDMFJTMTRxaE9QbG1sR1hlV2d3M2pzX2tSdXBVbTRiMjV2bmQ3elFucWR6SXIxeTQ5UXlxd1ppV1BNY01WTENja2tZcGFiSVg2RFBSbVA2Q3cxNXA5Z2x4STJFdHFkVkFxRlI5M0VLdGNHTFI3VzlDUXREUEZTdXNUUUk4UHJ0bFRZODhnOXU3dDQ2M256S19ZQVcwNjR0dndqQV9hZktVV2RJUGZEZ2dncERCWHh5WHhCRjF5cjFV?oc=5","date":"2026-03-04","type":"pipeline","source":"prnewswire.com","summary":"H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight - prnewswire.com","headline":"H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxPSkoyakxTdmVBZ1NKT29tN0JXNUF4d3F6VGtoVjVqZTJUYnFfT3k2MnlrUkk4eFRTdVRqLUZ3dXZDcmNQSFYzWjl0eDItZkZLMnlsaTRyZ0hwRFQtS19ZUEtmandZcjVRV1BvQ3N1QnJNcFdPT0tzOVU3WEt1ajNnYmpab01reVY1akY5S3VUbUVieFBiV2txOEhpQ05WWUNrRFpDdVFtVE1zM2lLRWRyWVl3dFVqVzJNRjhPM2NGekdSck51SG5sODJ4WGR1aGdEWXZWOFcwb0NFNFFNbktuQTQwMWlQRTd6VURpZ1QzUEdRelgzcldvblBrdFFEdEhDV0NjX1dodjNOLU5jZlBGZkFial9KQmg5MENHSWhwRnMwU0hrNUFidGF6Qm5YVUxMaDhkV0c5ODMwbVFOUy1MTFd3?oc=5","date":"2025-01-15","type":"trial","source":"GlobeNewswire","summary":"Liver Cirrhosis Clinical Trial Pipeline Experiences - GlobeNewswire","headline":"Liver Cirrhosis Clinical Trial Pipeline Experiences","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}